Allergan CEO opposes fundamental shift in strategy, shares fall

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. NVDA
5. STZ
6. MSFT
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to Allergan CEO opposes fundamental shift in strategy, shares fall

Allergan (AGN) & Medicines360 Highlight 5-Year Trial Data from Largest On-going IUS Clinical Study

April 30, 2018 8:38 AM EDT

Allergan plc (NYSE: AGN) and Medicines360 presented five-year data from their ongoing multi-center U.S.-based pivotal clinical trial investigating its intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, at the American College of Obstetricians and Gynecologists (ACOG) 2018 annual clinical and scientific meeting in Austin, Texas. The abstract presents five-year pregnancy rates (by Pearl Index and life-table analysis) and safety outcomes from the ongoing study. The Pearl Index in the first year, among women who were 1635 years old when they enrolled in the study, was 0.15 (CI: 0.02, 0.55). The cumulative life-table pregnancy rate at 5 years was 0.92 (CI:... More